» Articles » PMID: 29401273

Low Risk of Primary Clostridium Difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis

Overview
Journal Clin Infect Dis
Date 2018 Feb 6
PMID 29401273
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The choice of antibiotics for systemic infections in patients with a high risk of Clostridium difficile infection (CDI) remains a clinical practice dilemma. Although some studies suggest that tetracyclines may be associated with a lower risk of CDI than other antibiotics, other results are conflicting. We conducted a systematic review and metaanalysis of studies that assessed the risk of CDI with tetracyclines compared to other antibiotics.

Methods: We conducted a systematic search of Medline, Embase, and Web of Science from January 1978 through December 2016 to include studies that assessed the association between tetracycline use and risk of CDI. Weighted summary estimates were calculated using generalized inverse variance with a random-effects model using RevMan 5.3. Study quality was assessed using the Newcastle-Ottawa scale.

Results: Six studies (4 case control, 2 cohort) with patient recruitment between 1993 and 2012 were included. Metaanalysis using a random-effects model, demonstrated that tetracyclines were associated with a decreased risk of CDI (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.47-0.81; P < .001). There was significant heterogeneity, with an I2 of 53% with no publication bias. Subgroup analysis of studies that evaluated the risk of CDI with doxycycline alone also demonstrated a decreased risk of CDI (OR, 0.55; 95% CI, 0.40-0.75; P < .001).

Conclusions: Metaanalyses of existing studies suggest that tetracyclines may be associated with a decreased risk of CDI compared with other antimicrobials. It may be reasonable to use tetracyclines whenever appropriate to decrease CDI associated with antibiotic use.

Citing Articles

Community-Acquired Pneumonia for the Hospitalist: Updates and Controversies.

Bonsall J J Brown Hosp Med. 2025; 3(1):91180.

PMID: 40027389 PMC: 11864470. DOI: 10.56305/001c.91180.


infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.

Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M Clin Microbiol Rev. 2024; 37(2):e0013523.

PMID: 38421181 PMC: 11324037. DOI: 10.1128/cmr.00135-23.


A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.

Zurawski D, Serio A, Black C, Pybus B, Akers K, Deck D Mil Med. 2023; 189(5-6):e1353-e1361.

PMID: 37963013 PMC: 11110612. DOI: 10.1093/milmed/usad417.


Comparison of Different Antibiotics and the Risk for Community-Associated Infection: A Case-Control Study.

Miller A, Arakkal A, Sewell D, Segre A, Tholany J, Polgreen P Open Forum Infect Dis. 2023; 10(8):ofad413.

PMID: 37622034 PMC: 10444966. DOI: 10.1093/ofid/ofad413.


Treatment issues in recurrent infections and the possible role of germinants.

Budi N, Safdar N, Rose W FEMS Microbes. 2023; 1(1):xtaa001.

PMID: 37333958 PMC: 10117431. DOI: 10.1093/femsmc/xtaa001.